Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $61.9 million.

  • Centessa Pharmaceuticals' Cash from Investing Activities rose 37.77% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.4 million, marking a year-over-year decrease of 1360.67%. This contributed to the annual value of $31.3 million for FY2024, which is 124.62% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Cash from Investing Activities of $61.9 million as of Q3 2025, which was up 255.04% from -$40.0 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Investing Activities peaked at $61.9 million during Q3 2025, and registered a low of -$222.4 million during Q1 2025.
  • For the 3-year period, Centessa Pharmaceuticals' Cash from Investing Activities averaged around -$26.9 million, with its median value being -$18.3 million (2023).
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Cash from Investing Activities showed a top increase of 304,512.50% in 2023 and a maximum decrease of 35,873.33% in 2023.
  • Centessa Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$446,000 in 2022, then plummeted by 3,997.53% to -$18.3 million in 2023, then skyrocketed by 236.80% to $25.0 million in 2024, then surged by 37.77% to $61.9 million in 2025.
  • Its last three reported values are $61.9 million in Q3 2025, -$40.0 million for Q2 2025, and -$222.4 million during Q1 2025.